NK Cell-Specific CAR with DAP10 and 2B4 Domains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using chimeric antigen receptors (CARs) face challenges such as high production costs, immune side effects, and limited applicability due to the complexity of producing autologous CAR-T cells, which are not easily scalable or effective for all cancer types, particularly in reducing cytokine release syndrome and neurotoxicity.
Innovation Solution
Development of an NK cell-specific chimeric antigen receptor (CAR) comprising specific activation receptor domains, including an antigen-binding domain, CD8 or CD28 hinge domain, DAP10 cytoplasmic domain, 2B4 cytoplasmic domain, and CD3ζ cytoplasmic domain, expressed in NK cells to enhance their cytolytic activity against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous CAR-T cells are produced, then anticancer effect is improved, but production complexity and cost increase
Solution Approach 1:
The patent uses allogeneic NK cells as a copy alternative to autologous CAR-T cells. Instead of producing patient-specific CAR-T cells through complex genetic modification and expansion processes, the invention uses off-the-shelf allogeneic NK cells that can be rapidly produced and infused, thereby reducing production complexity while maintaining anticancer efficacy through the chimeric antigen receptor construct
Solution Approach 2:
The patent changes the cell type parameter from T cells to NK cells, and the source from autologous to allogeneic. This parameter change enables the use of commercially available allogeneic NK cell products combined with CAR construct, simplifying the production process while maintaining therapeutic effectiveness through the engineered receptor
2Reliability
If autologous CAR-T cells are produced, then anticancer effect is improved, but production cost increases
Solution Approach 1:
The patent employs allogeneic NK cells as a cost-effective alternative to autologous CAR-T production. By using commercially available allogeneic NK cell lines combined with standardized CAR constructs, the invention significantly reduces the high costs associated with personalized autologous T cell production, including genetic modification, expansion, and quality control procedures
Solution Approach 2:
The patent adopts the approach of using off-the-shelf allogeneic NK cells that can be rapidly produced and infused, similar to disposable medical devices. This eliminates the need for expensive, time-consuming autologous cell production processes while maintaining therapeutic efficacy through the engineered chimeric antigen receptor
3Reliability
If CAR-T cells are used, then cancer treatment is effective, but immune side effects occur
Solution Approach 1:
The patent uses allogeneic NK cells as a alternative to autologous CAR-T cells. Allogeneic NK cells have lower immunogenicity in the host compared to autologous T cells, reducing the risk of immune-related adverse events while maintaining cancer cell targeting capability through the chimeric antigen receptor construct
Solution Approach 2:
The patent changes the cell type from T cells to NK cells, which have different immunological characteristics. NK cells lack MHC restriction and have lower rates of graft-versus-host disease and immune-related side effects compared to T cells, thereby reducing harmful immune reactions while maintaining anticancer effectiveness
4Reliability
If CAR-T cell therapy is applied, then cancer treatment is effective, but cytokine release syndrome and neurotoxicity occur
Solution Approach 1:
The patent substitutes CAR-T cells with CAR-NK cells using allogeneic NK cells. Clinical data shows that CAR-NK therapy produces significantly lower rates of cytokine release syndrome and neurotoxicity compared to CAR-T therapy, while maintaining effective cancer cell killing through the chimeric antigen receptor-mediated activation of NK cell cytotoxicity
Solution Approach 2:
The patent changes the effector cell type from T cells to NK cells, which have different activation and regulation mechanisms. NK cells lack the MHC restriction and regulatory complexity of T cells, resulting in reduced cytokine release and neurotoxicity while maintaining effective cancer treatment through direct cytolytic activity and cytokine production
5Object-affected harmful factors
If NK cells are used, then side effects are reduced, but CAR construction complexity increases
Solution Approach 1:
The patent divides the CAR construct into modular functional domains: antigen-binding domain (scFv), hinge domain (CD8 or CD28), transmembrane domain, and cytoplasmic signaling domains (DAP10, 2B4, CD3ζ). This segmentation allows for standardized, interchangeable components that can be systematically assembled to create NK cell-specific CARs with optimized functionality and reduced construction complexity
Solution Approach 2:
The patent develops a universal CAR construction platform for NK cells using conserved and interchangeable domain modules. The hinge domain options (CD8 or CD28) and cytoplasmic domain combinations (DAP10, 2B4, CD3ζ) can be systematically combined to create multiple functional variants from a standardized set of components, reducing the complexity of de novo CAR construction while maintaining low side effect profiles
Data Source
AI summary
A chimeric antigen receptor (CAR), including an antigen-binding domain, a CD8 or CD28 hinge domain, a DAP10 cytoplasmic domain, a 2B4 cytoplasmic domain, and a CD3z cytoplasmic domain, where the CAR is expressed in natural killer (NK) cells. A method for treating cancer, including administering a therapeutically effective amount of a composition containing a NK cell that expresses the CAR, or a therapeutically effective amount of a cellular therapeutic agent containing a NK cell that expresses the CAR, to a subject in need thereof.